Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New trial aims to settle debate: stent or meds for clogged kidney arteries?

NCT ID NCT07511309

Disease control Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people with narrowed kidney arteries and high blood pressure. It uses a special pressure measurement (FFR) to decide who gets a stent and who gets only medication. The goal is to see which approach better protects kidney function and controls blood pressure over 12 months. About 300 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stent implantation and optimal medical therapy
What this could lead to
If successful, this could show that using FFR to guide stenting decisions improves blood pressure and kidney function better than medication alone.
What could go wrong
This trial hasn't started yet, and previous studies found stenting no better than medication. FFR guidance may not change that outcome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Renal artery diameter stenosis ≥60%; 2. Office systolic blood pressure ≥ 160 mmHg and/or office diastolic blood pressure ≥ 100 mmHg on at least two separate days without antihypertensive medication, or office systolic blood pressure ≥ 140 mmHg and/or office diastolic blood pressure ≥ 90 mmHg while on three antihypertensive drugs at conventional doses; 3. Serum creatinine \< 264 μmol/L (3.0 mg/dL); 4. Affected kidney length ≥ 7.0 cm, with residual glomerular filtration rate (GFR) ≥ 10 mL/min; Exclusion Criteria: 1. Unstable clinical condition rendering the patient intolerant to revascularisation therapy; 2. Urinary protein ≥2+; 3. Contrast medium allergy; 4. Renal artery anatomy unsuitable for revascularisation therapy; 5. Reference vessel diameter \<3.5mm or \>8mm. 6. Patients with non-atherosclerotic renal artery stenosis (such as fibromuscular dysplasia or Takayasu arteritis); 7. Reference vessel diameter \< 3.5 mm or \> 8 mm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic renal artery stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal artery atheroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerotic renal artery stenosis Fractional flow reserve Optimal medical therapy Stent implantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affilated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, 116001, China

  • China-Japan Union Hospital of Jilin University

    Changchun, Lilin, 130033, China

  • Department of Cardiovascular Medicine, Cardiovascular Research Center , The First Affiliated Hospital of Chongqing Medical University

    Chongqing, 400016, China

  • Frist Aiffiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Fuwai Central China Cardiovascular Hospital

    Zhengzhou, Henan, 450000, China

  • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, 100037, China

  • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)

    Guangzhou, Guangdong, China

  • Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)

    Nanchang, Jiangxi, 330038, China

  • Nanjing Pukou People's Hospital(Liangjiang Hospital Southeast University)

    Nanjing, Jiangsu, 211800, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Qingdao Hospital University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)

    Qingdao, Shandong, China

  • Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, 200025, China

  • The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China

    Chengdu, Sichuan, 610031, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510080, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510000, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150086, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150086, China

  • TianJin First Central Hospital

    Tianjin, 300192, China

  • Zhengzhou Central Hospital Affiliated to Zhengzhou University

    Zhengzhou, Henan, 450000, China

  • Zhengzhou Central Hospital Affiliated to Zhengzhou University

    Zhengzhou, Henan, 450007, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.